{"transactions":[{"id":4616820,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-14T20:05:20.000Z","date":"2026-09-10","kind":"grant","planned":false,"acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund, L.P. (the \"Nexus Fund\"), RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying common stock."}],"balance_after":16250,"derivative":{"exercise_price":10.42,"expiration_date":"2036-09-09","underlying":"Common Stock","underlying_shares":16250},"source":{"system":"sec-edgar","filing":"0001193125-26-390558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000119312526390558/ownership.xml","form_type":"4"}},{"id":3575944,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-09-08T21:58:07.000Z","date":"2026-09-08","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting."}],"balance_after":13750,"derivative":{"exercise_price":10.88,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001193125-26-385419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000119312526385419/ownership.xml","form_type":"4"}},{"id":748187,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:27:28.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":53250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option and RSUs for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":53250,"derivative":{"exercise_price":2.29,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":53250},"source":{"system":"sec-edgar","filing":"0001628280-26-041263","document":"wk-form4_1780691244.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000162828026041263/wk-form4_1780691244.xml","form_type":"4"}},{"id":748186,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:27:28.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":35500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option and RSUs for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":48300,"source":{"system":"sec-edgar","filing":"0001628280-26-041263","document":"wk-form4_1780691244.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000162828026041263/wk-form4_1780691244.xml","form_type":"4"}},{"id":1101142,"issuer":{"id":5404,"kind":"organization","name":"Artiva Biotherapeutics, Inc.","symbol":"ARTV"},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-06-26T20:30:15.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":13750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of  June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the \"Fund\"), the R.A. Capital Nexus Fund, L.P. (the \"Nexus Fund\"), the RA Capital Nexus Fund III, L.P. (the \"Nexus Fund III\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":13750,"derivative":{"exercise_price":1.61,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":13750},"source":{"system":"sec-edgar","filing":"0001415889-25-018280","document":"form4-06262025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000141588925018280/form4-06262025_040612.xml","form_type":"4"}},{"id":1121508,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T22:05:34.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option and RSUs for the benefit of the R.A. Capital Healthcare Fund, L.P. (the \"Fund\"), R.A. Capital Nexus Fund II, L.P. (the \"Nexus Fund II\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement, as applicable, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":19500,"derivative":{"exercise_price":1.07,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001576885-25-000084","document":"wk-form4_1749160924.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000157688525000084/wk-form4_1749160924.xml","form_type":"4"}},{"id":1121507,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T22:05:34.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":12800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option and RSUs for the benefit of the R.A. Capital Healthcare Fund, L.P. (the \"Fund\"), R.A. Capital Nexus Fund II, L.P. (the \"Nexus Fund II\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement, as applicable, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock."}],"balance_after":12800,"source":{"system":"sec-edgar","filing":"0001576885-25-000084","document":"wk-form4_1749160924.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000157688525000084/wk-form4_1749160924.xml","form_type":"4"}},{"id":1485164,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T20:51:59.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 10, 2025 or the 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the \"Fund\"), R.A. Capital Nexus Fund II, L.P. (the \"Nexus Fund II\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":25000,"derivative":{"exercise_price":2.62,"expiration_date":"2034-06-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001576885-24-000084","document":"wk-form4_1718052712.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000157688524000084/wk-form4_1718052712.xml","form_type":"4"}},{"id":1864120,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-07T21:44:36.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 6, 2024 or the 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":25000,"derivative":{"exercise_price":5.2,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001576885-23-000036","document":"wk-form4_1686174265.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000157688523000036/wk-form4_1686174265.xml","form_type":"4"}},{"id":2228266,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T20:27:09.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\") and a separately managed account (the \"Account\"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":25000,"derivative":{"exercise_price":3.59,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-22-037887","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000120919122037887/doc4.xml","form_type":"4"}},{"id":2645320,"issuer":{"id":6281,"kind":"organization","name":"Acumen Pharmaceuticals, Inc."},"owners":[{"id":40979,"kind":"person","name":"Stoppel Laura","position":1,"cik":"0001865119","reported_name":"Stoppel Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T20:21:52.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Under the Reporting Person's arrangement with RA Capital Management, L.P. (the \"Adviser\"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the \"Fund\"), RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\") and a separately managed account (the \"Account\").  The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser.  The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."}],"balance_after":34000,"derivative":{"exercise_price":16,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001209191-21-044959","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865119/000120919121044959/doc4.xml","form_type":"4"}}]}